Get the Stockscreener App
2.29
6.53%
-0.16
After Hours:
2.20
-0.09
-3.93%
Processa Pharmaceuticals Inc stock is traded at $2.29, with a volume of 54,039.
It is down -6.53% in the last 24 hours and down -27.07% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$2.45
Open:
$2.56
24h Volume:
54,039
Relative Volume:
0.07
Market Cap:
$5.19M
Revenue:
-
Net Income/Loss:
$-12.88M
P/E Ratio:
-0.9864
EPS:
-2.3215
Net Cash Flow:
$-10.85M
1W Performance:
+5.53%
1M Performance:
-27.07%
6M Performance:
-58.50%
1Y Performance:
-84.97%
1-Day Range:
$2.25
$2.56
1-Week Range:
$2.10
$2.56
52-Week Range:
$2.05
$19.63
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.29 | 5.55M | 0 | -12.88M | -10.85M | -2.3215 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Aug Technicals: Does Processa Pharmaceuticals Inc have a sustainable dividendJuly 2025 Volume & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Erie Times-News
Is Processa Pharmaceuticals Inc likely to announce a buybackGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Fed Meeting: Should I hold or sell Processa Pharmaceuticals Inc nowWeekly Market Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Jobs Data: What makes MNTK stock attractive todayJuly 2025 Sector Moves & Real-Time Market Trend Scan - baoquankhu1.vn
Why did Processa Pharmaceuticals stock surge 160% today? - MSN
Big Picture: Does Processa Pharmaceuticals Inc have a sustainable dividendInsider Buying & Accurate Buy Signal Alerts - baoquankhu1.vn
Pharma Sector Update: Amneal Valuation, Processa Profile, and Balaxi Earnings - scoopsquare24.com
Big Money Moves: Can Processa Pharmaceuticals Inc maintain sales growth2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Patterns Watch: Does Processa Pharmaceuticals Inc align with a passive investing strategy - baoquankhu1.vn
ETF Watch: Will Processa Pharmaceuticals Inc benefit from current market trendsQuarterly Trade Review & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Times Herald-Record
Risk Hedge: Is Processa Pharmaceuticals Inc showing insider buyingRate Cut & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Processa Pharmaceuticals completes enrollment of 20th patient in Phase 2 study - MSN
Will Processa Pharmaceuticals Inc. benefit from current market trendsBull Run & AI Enhanced Execution Alerts - bollywoodhelpline.com
History Review: Should value investors consider Processa Pharmaceuticals IncJuly 2025 Closing Moves & Weekly Market Pulse Updates - baoquankhu1.vn
Stock Recap: Is Processa Pharmaceuticals Inc showing insider buying2025 Market WrapUp & Real-Time Market Sentiment Reports - baoquankhu1.vn
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference to Discuss NGC-Cap Phase 2 Study Results - Quiver Quantitative
Is Processa Pharmaceuticals Inc. stock supported by strong cash flowsMarket Risk Report & Fast Gain Swing Trade Alerts - ulpravda.ru
How Processa Pharmaceuticals Inc. stock reacts to oil pricesWeekly Gains Summary & Technical Buy Zone Confirmation - Улправда
User - FinancialContent
Will Processa Pharmaceuticals Inc. stock outperform value stocksLayoff News & Capital Efficiency Focused Strategies - Улправда
Biostar Pharmaceuticals (OTCMKTS:BSPM) versus Heatwurx (NASDAQ:PCSA) Critical Review - Defense World
Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance - TipRanks
Processa Pharmaceuticals shares surge on encouraging cancer trial update - MSN
Processa Pharmaceuticals completes enrollment for NGC-Cap breast cancer study - Investing.com Nigeria
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):